4. (once amended) The method of claim 21, wherein said active agent is selected from the group consisting of human CGRP and rat CGRP.

6. (once amended) The method of claim 21, wherein said active agent has a purity of at least 95 to 98%.

7. (once amended) The method of claim 21, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.

21. (once amended) A method for the reduction of:

(i) agonist-induced bronchoconstriction;

(ii) agonist-induced bronchospasm;

(iii) allergen-induced bronchospasm;

(iv) lung inflammation caused by increased eosinophilia;

(v) airway hyperreactivity; or

(vi) any combination of (i) to (v);

wherein said method comprises the administration of an active agent selected from the group consisting of:

a) human calcitonin gene-related peptide (human CGRP);

b) rat CGRP;

c) diacetoamidomethyl cysteine form of (a) ([Cys(ACM)^{2,7}] human CGRP); and

d) diacetoamidomethyl cysteine form of (b) ([Cys(ACM)^{2,7}] rat CGRP).

Please add new claims 27 to 30 as follows:

27. (new) The method of claim 4 wherein said active agent is selected from the group consisting of human α CGRP and rat α CGRP.

28. (new) The method of claim 21, wherein said active agent is selected from the group consisting of the diacetoamidomethyl cysteine form of human CGRP ([Cys(ACM)^{2,7}] human CGRP) and the diacetoamidomethyl cysteine form of rat CGRP ([Cys(ACM)^{2,7}] rat CGRP).

29. (new) The method of claim 28, wherein said active agent is selected from the group consisting of the diacetoamidomethyl cysteine form of human α CGRP ([Cys(ACM)^{2,7}] human α CGRP) and the diacetoamidomethyl cysteine form of rat α CGRP ([Cys(ACM)^{2,7}] rat α CGRP).

30. (new) A method for the reduction of:

(i) agonist-induced bronchoconstriction;

(ii) agonist-induced bronchospasm;

(iii) allergen-induced bronchospasm;

(iv) lung inflammation caused by increased eosinophilia;

(v) airway hyperreactivity; or

(vi) any combination of (i) to (v);

wherein said method comprises the administration of an active agent selected from the group consisting of:

a) human calcitonin gene-related peptide (human CGRP);

b) rat CGRP;

c) cow CGRP;

d) pig CGRP;

e) chicken CGRP;

f) frog CGRP; and

g) diacetoamidomethyl cysteine forms of (a) to (f) ([Cys(ACM)^{2,7}]CGRP).

REMARKS

Claims 2, 4 to 8, 21 and 27 to 30 are pending. Applicant has cancelled claims 3, 9 to 20 and 22 to 26 without prejudice or disclaimer, amended claims 4, 6, 7 and 21, and